MedTrace Logo

Effects of Metformin on Metabolic and Reproductive Outcomes in Chinese PCOS Patients

NCT05463627 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1440

Last updated 2022-07-19

No results posted yet for this study

Summary

Polycystic ovary syndrome (PCOS) is a reproductive endocrine disease characterized by reproductive and metabolic abnormalities, which is a crucial cause of female infertility and an essential risk factor for type 2 diabetes. At present, there exist several clinical trials and studies on the usage of metformin in the treatment of PCOS patients in prediabetes, and the practical application of metformin in clinical practice has years of history. The treatment plan of metformin is of great significance in preventing type 2 diabetes in PCOS patients and assisting pregnancy in PCOS infertile patients.

Conditions

Interventions

DRUG

Metformin

All participants among the three groups were treated with metformin

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Tao Tao, Dr. · RenJi Hospital

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2023-01-01
Completion
2023-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05463627 on ClinicalTrials.gov